Drug Approval | May 19, 2026
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Baxfendy works in a fundamentally different way from current therapies
Baxfendy works in a fundamentally different way from current therapies
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Subscribe To Our Newsletter & Stay Updated
